Abstract
Erectile dysfunction (ED) is the main and most frequent side effect after radical prostatectomy. Also, ED is the primary impact factor for quality of life after radical prostatectomy. ED post radical prostatectomy is mainly due to lesions in the neurovascular bundles which can occur by partial or total sectioning, by stretching (the most common), or by thermal lesion of the nervous fibers, leading to a condition called “neuropraxia”. The term penile rehabilitation (PR) after prostatectomy has been defined as any intervention with the intent of reestablishing preoperative erectile function and includes the isolated or combined use of phosphodiesterase 5 inhibitors (PDE5i), intracavernous injection, vacuum erectile device therapy, and use of intraurethral drugs. The use of intracavernous drugs, of intraurethral prostaglandin and the use of vacuum therapy have a poorly defined role regarding postoperative penile rehabilitation and must be better investigated through further studies. The use of PDE5i as PR is strongly supported by experimental research, but most clinical trials found controversial results.
Keywords: Erectile dysfunction, penis erection, prostatectomy, penile function, phosphodiesterase type 5 inhibitors, prostate cancer, rehabilitation.
Current Drug Targets
Title:Penile Rehabilitation After Radical Prostatectomy
Volume: 16 Issue: 5
Author(s): David Jacques Cohen and Sidney Glina
Affiliation:
Keywords: Erectile dysfunction, penis erection, prostatectomy, penile function, phosphodiesterase type 5 inhibitors, prostate cancer, rehabilitation.
Abstract: Erectile dysfunction (ED) is the main and most frequent side effect after radical prostatectomy. Also, ED is the primary impact factor for quality of life after radical prostatectomy. ED post radical prostatectomy is mainly due to lesions in the neurovascular bundles which can occur by partial or total sectioning, by stretching (the most common), or by thermal lesion of the nervous fibers, leading to a condition called “neuropraxia”. The term penile rehabilitation (PR) after prostatectomy has been defined as any intervention with the intent of reestablishing preoperative erectile function and includes the isolated or combined use of phosphodiesterase 5 inhibitors (PDE5i), intracavernous injection, vacuum erectile device therapy, and use of intraurethral drugs. The use of intracavernous drugs, of intraurethral prostaglandin and the use of vacuum therapy have a poorly defined role regarding postoperative penile rehabilitation and must be better investigated through further studies. The use of PDE5i as PR is strongly supported by experimental research, but most clinical trials found controversial results.
Export Options
About this article
Cite this article as:
Cohen Jacques David and Glina Sidney, Penile Rehabilitation After Radical Prostatectomy, Current Drug Targets 2015; 16 (5) . https://dx.doi.org/10.2174/1389450116666150202153832
DOI https://dx.doi.org/10.2174/1389450116666150202153832 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Carboplatin in the Treatment of Triple Negative Early- Stage Breast Cancer
Reviews on Recent Clinical Trials TGF-beta Signaling in Cancer Treatment
Current Pharmaceutical Design Unexpected High Levels of Vorinostat when Combined with Vinorelbine in Patients with Advanced Cancer
Current Clinical Pharmacology Molecular Targeted Therapies in the Management of Head and Neck Squamous Cell Carcinoma: Recent Developments and Perspectives
Anti-Cancer Agents in Medicinal Chemistry Translational Gap in Glioma Research
Anti-Cancer Agents in Medicinal Chemistry JAK Inhibitors: Pharmacology and Clinical Activity in Chronic Myeloprolipherative Neoplasms
Current Medicinal Chemistry Antibody-Based Targeted Interventions for the Diagnosis and Treatment of Skin Cancers
Anti-Cancer Agents in Medicinal Chemistry Interleukin-26, a Highly Cationic T-Cell Cytokine Targeting Epithelial Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Modulating Fatty Acid Metabolism and the AMP-Activated Protein Kinase Pathway as a Target for Obesity Therapy
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents BUB1B Promotes Proliferation of Prostate Cancer via Transcriptional Regulation of MELK
Anti-Cancer Agents in Medicinal Chemistry Accessing Cancer Metabolic Pathways by the Use of Microarray Technology
Current Pharmaceutical Design Angiogenesis Inhibitors: Current & Future Directions
Current Pharmaceutical Design Genetic Variations in Telomere Maintenance, with Implications on Tissue Renewal Capacity and Chronic Disease Pathologies
Current Pharmacogenomics and Personalized Medicine A Nanotechnology-based Strategy to Increase the Efficiency of Cancer Diagnosis and Therapy: Folate-conjugated Gold Nanoparticles
Current Medicinal Chemistry Meet Our Editorial Board Member:
Recent Patents on Regenerative Medicine Carvacrol Exhibits Chemopreventive Potential against Cervical Cancer Cells via Caspase-Dependent Apoptosis and Abrogation of Cell Cycle Progression
Anti-Cancer Agents in Medicinal Chemistry Suicide Gene Therapy Against Malignant Gliomas by the Local Delivery of Genetically Engineered Umbilical Cord Mesenchymal Stem Cells as Cellular Vehicles
Current Gene Therapy Pharmacogenomics of Human ABC Transporter ABCC11 (MRP8): Potential Risk of Breast Cancer and Chemotherapy Failure
Anti-Cancer Agents in Medicinal Chemistry Coumarin Compounds in Medicinal Chemistry: Some Important Examples from the Last Years
Current Topics in Medicinal Chemistry Nano-Delivery in Pediatric Tumors: Looking Back, Moving Forward
Anti-Cancer Agents in Medicinal Chemistry